Patent application number | Description | Published |
20090298184 | Polypeptide Markers for the Diagnosis of Prostate Cancer - A method for the diagnosis of prostate cancer, comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the polypeptide marker is selected from markers 1 to 44 and 52 to 78 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 45 to 51 and 79 to 115 (amplitude markers), wherein said sample is a urine sample or seminal fluid sample. | 12-03-2009 |
20100036094 | Polypeptide Markers for the Diagnosis of Alzheimer's Disease - A method for the diagnosis of Alzheimer's disease, comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein the polypeptide marker is selected from markers 1 to 50 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 51 to 279 (amplitude markers) | 02-11-2010 |
20100062537 | Polypeptide Markers for the Diagnosis and Evaluation of Pelvi-Ureteric Junction Obstruction (PUJO) - A process for diagnosing pelvi-ureteric junction obstruction (PUJO), comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 277 (frequency markers), or of determining the amplitude of at least one polypeptide marker selected from markers 278-308 (amplitude markers), which are characterized by values for the molecular masses and migration times (CE times). | 03-11-2010 |
20100099196 | PROCESS FOR NORMALIZING THE CONCENTRATION OF ANALYTES IN A URINE SAMPLE - Process for normalizing the concentration of at least one analyte in a urine sample, comprising the following steps:
| 04-22-2010 |
20100200401 | Polypeptide Markers for the Early Recognition of the Rejection of Transplanted Kidneys - A method for recognizing rejection after a kidney transplantation (NTx), comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 242 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 243 to 767 (amplitude markers), which are characterized by the values for the molecular masses and migration times (CE time). | 08-12-2010 |
20100210021 | PROCESS AND MARKERS FOR THE DIAGNOSIS OF KIDNEY DISEASES - A process for the diagnosis of kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times. | 08-19-2010 |
20100227411 | POLYPEPTIDE MARKERS FOR THE DIAGNOSIS OF PROSTATE CANCER - A method for the diagnosis of prostate diseases, comprising the step of determining an amplitude or the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 141, which are characterized by values for the molecular masses and migration times. | 09-09-2010 |
20100248378 | METHOD AND MARKER FOR DIAGNOSING DIABETES MELLITUS - A process for the diagnosis of diabetes mellitus comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized by the values for the molecular masses and migration times according to Table 1. | 09-30-2010 |
20110036717 | METHOD AND MARKER FOR DIAGNOSIS OF TUBULAR KIDNEY DAMAGE AND ILLNESS - A method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide marker being selected from the markers characterized in Table 1 by values for the molecular masses and migration times. | 02-17-2011 |
20110281364 | METHOD AND MARKER FOR DIAGNOSING DIABETES MELLITUS - A process for the diagnosis of diabetes mellitus comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized by the values for the molecular masses and migration times according to Table 1. | 11-17-2011 |
20120037507 | METHOD AND MARKER FOR DIAGNOSIS OF TUBULAR KIDNEY DAMAGE AND ILLNESSES - A method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide marker being selected from the markers characterized in Table 1 by values for the molecular masses and migration times. | 02-16-2012 |
20120118737 | Method And Markers For Diagnosing Acute Renal Failure - The invention relates to a method for diagnosing acute renal failure, comprising the step of determining a presence or absence or amplitude of at least three polypeptide markers in a sample, wherein the polypeptide marker is among the markers characterized in table 1 by values for the molecular weights and the migration time. | 05-17-2012 |
20120241321 | POLYPEPTIDE MARKER FOR DIAGNOSING AND ASSESSING VASCULAR DISEASES - The invention relates to a method for diagnosing vascular diseases, comprising the step in which the presence, absence or amplitude of at least three polypeptide markers is determined in a urine sample, wherein the polypeptide markers are selected from the markers characterized in table 1 by values for the molecular masses and the migration time. | 09-27-2012 |
20140027283 | METHOD AND MARKER FOR THE DIAGNOSIS OF A BILE DUCT STRICTURE AND OF A CHOLANGIOCELLULAR CARCINOMA IN BILE - A method for the diagnosis of a benign or malignant bile duct stricture and/or of a CCC, comprising the step of determining at least three polypeptide markers in a body fluid, wherein the polypeptide marker belongs to those markers which in table 1 and/or table 2 a and/or b are characterized by values for the molecular mass and the migration time. | 01-30-2014 |
20140073057 | PROCESS AND MARKERS FOR THE DIAGNOSIS OF KIDNEY DISEASES - A process for the diagnosis of kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times. | 03-13-2014 |
20150018246 | POLYPEPTIDE MARKER FOR DIAGNOSING AND ASSESSING VASCULAR DISEASES - The invention relates to a method for diagnosing vascular diseases, comprising the step in which the presence, absence or amplitude of at least three polypeptide markers is determined in a urine sample, wherein the polypeptide markers are selected from the markers characterized in table 1 by values for the molecular masses and the migration time. | 01-15-2015 |
20150024970 | KIDNEY CELL CARCINOMA - The process for the diagnosis of a renal cell carcinoma comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, wherein said polypeptide markers are selected from the markers as characterized in Table 1 by molecular masses and migration times. | 01-22-2015 |
20150065391 | POLYPEPTIDE MARKERS FOR DIAGNOSIS AND ASSESSMENT OF HEART FAILURE - Method for diagnosis of heart failure, comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and the migration time. | 03-05-2015 |
20150087554 | POLYPEPTIDE MARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE - A method for the diagnosis of the probability of Alzheimer's disease in a subject patient comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the at least three polypeptide markers are at least three different markers selected from markers 1 to 50 (frequency markers) and markers 51 to 279 (amplitude markers), wherein the diagnosis is based on a comparison and ranking of the frequency and/or amplitude of the at least three polypeptide markers to the same at least three polypeptide markers obtained from control subjects with and without Alzheimer's disease. | 03-26-2015 |